Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

(2011) Chungyeul Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties and are regulated by HER2 expression and signalling

(2010) T Nakanishi et al.   BRITISH JOURNAL OF CANCER

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

(2010) X. Huang et al.   CANCER RESEARCH

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer

(2010) Rohit Bhargava et al.   MODERN PATHOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Direct multiplexed measurement of gene expression with color-coded probe pairs

(2008) Gary K Geiss et al.   NATURE BIOTECHNOLOGY

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE